Verastem, Inc. (NASDAQ:VSTM)

CAPS Rating: 3 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar OklaBoston (61.56) Submitted: 5/29/2015 9:44:41 AM : Outperform Start Price: $8.82 VSTM Score: -1.53

Earnings turnaround speculation.

Recs

0
Member Avatar Haugurafpeningum (28.26) Submitted: 5/4/2015 7:07:17 AM : Outperform Start Price: $8.58 VSTM Score: +0.86

Insider Monkey. Improving OBV

Recs

0
Member Avatar akamaidude (< 20) Submitted: 1/10/2014 10:09:15 PM : Outperform Start Price: $13.57 VSTM Score: -51.19

Promising technology and approach for cancer treatment and cure.

Recs

0
Member Avatar TruffelPig (< 20) Submitted: 10/27/2013 4:41:54 PM : Outperform Start Price: $11.26 VSTM Score: -43.22

MIT creme de la creme.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 5:22:16 PM : Underperform Start Price: $14.67 VSTM Score: +67.81

Short. No revenues… if gets some might change to neutral.

Recs

0
Member Avatar cowman1 (< 20) Submitted: 1/24/2013 4:26:15 PM : Outperform Start Price: $10.21 VSTM Score: -56.15

USB analyst Matthew Roden thinks the company has a formular likely to prove crucial in the fight against many types of cancer.

Recs

3
Member Avatar zzlangerhans (99.80) Submitted: 8/15/2012 2:14:07 PM : Outperform Start Price: $8.18 VSTM Score: -44.05

Verastem took a body blow with the news that salinomycin was no longer in line for clinical trials, and cushioned the blow with the announcement of a new partnership with Eisai. The company is still keeping a lid on much of what they're doing but I see a low market cap, a solid cash position, and an experienced management team. While my skepticism level remains high, I'll look for a leg back up from here.

Results 1 - 7 of 7

Featured Broker Partners


Advertisement